TScan Therapeutics annual capital expenditures (capex)
2020
2021
2022
2023
2024
2025
TScan Therapeutics Capital Expenditures (CapEx) Growth & History (TCRX)
TScan Therapeutics's capital expenditures (capex) was $4.4M for fiscal 2025.
View full TScan Therapeutics company overviewTScan Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.4M | $582,000 | +15.22% |
| 2024 | 2024-12-31 | $3.8M | $679,000 | +21.58% |
| 2023 | 2023-12-31 | $3.1M | −$1.1M | −25.54% |
| 2022 | 2022-12-31 | $4.2M | −$5.7M | −57.50% |
| 2021 | 2021-12-31 | $9.9M | $5.7M | +134.57% |
| 2020 | 2020-12-31 | $4.2M | — | — |
TScan Therapeutics quarterly capital expenditures (capex)
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $493,000 | −$786,000 | −61.45% |
| Q1 2026 | 2026-03-31 | $70,000 | −$1.5M | −95.43% |
| Q4 2025 | 2025-12-31 | $171,000 | −$717,000 | −80.74% |
| Q3 2025 | 2025-09-30 | $1.4M | $55,000 | +4.01% |
| Q2 2025 | 2025-06-30 | $1.3M | $417,000 | +48.38% |
| Q1 2025 | 2025-03-31 | $1.5M | $827,000 | +117.30% |
| Q4 2024 | 2024-12-31 | $888,000 | $419,000 | +89.34% |
| Q3 2024 | 2024-09-30 | $1.4M | −$49,000 | −3.45% |
| Q2 2024 | 2024-06-30 | $862,000 | $442,000 | +105.24% |
| Q1 2024 | 2024-03-31 | $705,000 | −$133,000 | −15.87% |
| Q4 2023 | 2023-12-31 | $469,000 | −$908,000 | −65.94% |
| Q3 2023 | 2023-09-30 | $1.4M | $995,000 | +234.67% |
| Q2 2023 | 2023-06-30 | $420,000 | −$1.5M | −77.81% |
| Q1 2023 | 2023-03-31 | $838,000 | $307,000 | +57.82% |
| Q4 2022 | 2022-12-31 | $1.4M | −$834,000 | −37.72% |
| Q3 2022 | 2022-09-30 | $424,000 | −$429,000 | −50.29% |
| Q2 2022 | 2022-06-30 | $1.9M | −$2.0M | −51.68% |
| Q1 2022 | 2022-03-31 | $531,000 | −$2.4M | −82.05% |
| Q4 2021 | 2021-12-31 | $2.2M | — | — |
| Q3 2021 | 2021-09-30 | $853,000 | −$490,000 | −36.49% |
| Q2 2021 | 2021-06-30 | $3.9M | — | — |
| Q1 2021 | 2021-03-31 | $3.0M | — | — |
| Q3 2020 | 2020-09-30 | $1.3M | — | — |
TScan Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, TScan Therapeutics's capital expenditures (capex) increased from $4.2M to $4.4M, a change of $169,000. The latest reported quarter, Q2 2026, shows $493,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review TScan Therapeutics source filings ↗